GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million
Tuesday, October 6, 2026 · first reported by HedgeCo
Trilantic North America agrees to sell SOFIE Biosciences (PET radiopharmaceutical contract manufacturer) to GE HealthCare for $945M; SOFIE operates 15 U.S. manufacturing sites with 21 cyclotrons and U.S. rights to FAPI-74 experimental imaging agent.
- Also named
- GE HealthCare, SOFIE Biosciences
- Deal value
- $945M
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore in Deals
From the same day- CD&R and McKesson ink $5.8bn take-private deal for Option Care HealthPE Hub +2
- CPP Investments to sell Australian toll road assets to Transurban for $3bIREI
- Clean Harbors completes $470M acquisition of EnviroServe from One Rock Capital Partners (acquired Jan 2023 at ~17.4x adjPrivate Equity Professional
- Sojourner unveils $279m Lornamead-AMG Brands merger to form LPNA GroupPE Hub
- Verlinvest and Family Trust Investor combine bouldering brands into 39-gym platformPE Hub
- Kohlberg takes majority stake in Black Bay-backed Advanced Industrial DevicesPE Hub